Berenberg Starts Neon Therapeutics (NTGN) at Buy

Berenberg analyst Shanshan Xu initiates coverage on Neon Therapeutics (NASDAQ: NTGN) with a Buy rating and a price target of $15.00.

The analyst comments "Neon has generated compelling immunological data for its NEO-PV-01 personalized neoantigen vaccine. Additionally, early clinical data points to a clear efficacy signal, something which we believe is not well understood by the Street. We think the positive results generated to-date may translate into a clinical benefit in a larger patient population. Therefore, we are bullish on the 52-week clinical data readout for the Phase I NT-001 study, expected H119."

For an analyst ratings summary and ratings history on Neon Therapeutics click here. For more ratings news on Neon Therapeutics click here.

Shares of Neon Therapeutics closed at $5.17 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• HSBC Upgrades Sembcorp Industries (SCI:SP) to Buy
• BMO Capital Starts Energy Fuels (UUUU) at Outperform